Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-14

Study Completion Date

2020-08-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study was not opened.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Convalescent Plasma to Limit Coronavirus Associated Complications

NCT04325672

Coronavirus

WITHDRAWN PHASE2

Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19

NCT04467151

COVID-19

WITHDRAWN PHASE2

Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness

NCT04642014

COVID-19 Convalescent Plasma Treatment

TERMINATED NA

Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19

NCT05271929

COVID-19

TERMINATED PHASE3

Use of Convalescent Plasma for COVID-19

NCT04408040

COVID

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID Sars-CoV2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Convalescent subjects

Convalescent, now asymptomatic, subjects with documented prior COVID-19 due to SARS-CoV-2 infection

No interventions assigned to this group

Healthy controls

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients who have previously been diagnosed with COVID-19 but are now asymptomatic \>14 days and a matched number of healthy controls:

1. Consent: Subject able to provide voluntary written consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
2. SARS-CoV-2 Testing Status:

1. Experimental Population: Subject has had positive SARS-CoV-2 verified by clinical laboratory OR
2. Control Population: Subject without testing or negative SARS-CoV-2 testing
3. Complete resolution and current absence of clinical symptoms Symptoms Defined as: Fever, Dry cough, Fatigue, Difficulty breathing, Sore throat, Diarrhea, Rhinorrhea (runny nose), or new aches/pains.
4. Age: Greater or equal to 18 years of age. a. Subject must be able to provide voluntary written consent

Exclusion Criteria

1. Ongoing symptoms of COVID19 due to SARS-CoV-2 infection

a. Symptoms Defined as: Fever, Dry cough, Fatigue, Difficulty breathing, Sore throat, Diarrhea, Rhinorrhea (runny nose), or new aches/pains.
2. Ongoing symptoms not due or not known to be due to SARS-CoV-2 infection

a. Symptoms Defined as: Fever, Dry cough, Fatigue, Difficulty breathing, Sore throat, Diarrhea, Rhinorrhea (runny nose), or new aches/pains.
3. Patients receiving ongoing medical symptomatic treatment or prophylaxis treatment related to COVID-19 due to SARS-CoV-2

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes